Nvidia Unveils Expanded AI Platform to Accelerate Drug Discovery
At GTC 2024, Nvidia CEO Jensen Huang introduces an expanded BioNeMo platform and new NIMs technology to streamline access to generative AI models. These innovations aim to transform genomics and pharmaceutical research through strategic cloud partnerships.
Nvidia founder and CEO Jensen Huang captivates audiences at the GTC 2024 AI developer conference by announcing major advancements tailored for the life sciences sector. The company reveals an expanded NVIDIA BioNeMo generative AI platform, which is specifically designed to accelerate and streamline the complex process of drug discovery.
To make these advanced artificial intelligence models more accessible to researchers, Nvidia introduces NVIDIA Inference Microservices, or NIMs. This new technology allows users to easily integrate and access AI models without needing to build the underlying infrastructure from scratch, significantly lowering the barrier to entry for biotech innovators.
These technological leaps are further bolstered by strategic expanded collaborations with major cloud providers, including Amazon Web Services and Microsoft Azure. By combining these new tools with massive cloud computing power, Nvidia actively drives a rapid AI revolution that promises to reshape genomics and pharmaceutical development.